Last Updated: June 30, 2026

Suppliers and packagers for estring


✉ Email this page to a colleague

« Back to Dashboard


estring

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Pfizer ESTRING estradiol INSERT, EXTENDED RELEASE;VAGINAL 020472 NDA Pfizer Laboratories Div Pfizer Inc 0013-1042-01 1 POUCH in 1 CARTON (0013-1042-01) / 1 SYSTEM in 1 POUCH 2023-06-05
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

ESRING (estradiol vaginal ring) Suppliers: Who Manufactures, Packs, and Supplies Estring for Distribution

Last updated: June 11, 2026

ESRING (estradiol vaginal ring) is supplied through a defined manufacturer and packaging network, with product release and distribution handled by branded commercialization channels. Without specific, source-linked information for the current commercial supply chain (current manufacturer, sites, packager, and distributor by country/market), a complete and accurate supplier list cannot be produced.

Who supplies Estring (estradiol vaginal ring) to pharmacies and hospitals?

Featured answer: Estring supply is controlled through a branded distribution chain that typically includes: (1) the ring manufacturer (drug substance and/or finished ring), (2) a packaging/secondary packaging site, and (3) a market authorization holder and distributor responsible for release and distribution.

Key supply-chain roles for Estring

  • Primary manufacturer: Produces the estradiol-containing vaginal ring bulk and/or finished ring.
  • Packaging site: Secondary packs (cartons) and unit-of-use packaging.
  • Market supply/distribution: Handles country-specific distribution agreements and wholesaler supply.

What entities usually appear as “manufactured by” on Estring packaging?

On marketed product labels, the following patterns are common:

  • “Manufactured by” (drug product manufacturer)
  • “Distributed by” (market distribution company)
  • “Batch released by” (product release entity, sometimes shown as manufacturer/release site)
  • “Packaged by” / “Secondary packaged by” (packaging site)

Which companies make Estring vaginal rings (manufacturers and packagers)?

Featured answer: A defensible manufacturer and packager list requires current label/registration evidence (country SmPC, PIL, label, or authoritative regulatory databases). That information is not available in the prompt.

What data sources typically identify Estring suppliers?

  • National drug regulatory databases and product registers
  • EMA national-level product documentation (if applicable)
  • FDA Orange Book entry (if US-registered product exists in scope)
  • Estring SmPC/PIL and current package leaflet
  • Wholesale distribution label text (carton and blister insert)

What is the Orange Book status of Estring and how does it map to suppliers?

Featured answer: Orange Book mappings require a specific US NDA/BLA entry for Estring and the listed applicant/manufacturer. Without the NDA number and Orange Book listing details, supplier mapping cannot be compiled.

Do generics or authorized alternatives for Estring change supplier risk?

Featured answer: Supplier diversification depends on the presence of approved generic/authorized alternatives and their manufacturing approvals. Without product-specific approval listings, supplier risk for substitution cannot be quantified.

How do regulatory changes affect Estring supply continuity?

Featured answer: Supply continuity is affected by manufacturing site approvals, batch release, and labeling updates required after regulatory changes. A supplier timeline requires evidence of site changes or recalls tied to named entities.

What typically triggers supplier changes for vaginal ring products?

  • GMP inspection outcomes by site
  • Contract manufacturing shifts
  • Packaging line changes
  • Regulatory variations affecting device component materials or ring release characteristics

What supplier due diligence documents are required for Estring sourcing?

Featured answer: For procurement and compliance, due diligence typically covers:

  • GMP certificate for the manufacturing and packaging sites
  • Written confirmation of market authorization responsibility
  • Batch CoA availability and release location
  • Supply chain traceability for ring components
  • Stability and packaging integrity documentation

Key Takeaways

  • Estring supply is managed through manufacturer, packaging, and market distribution roles, but a complete named supplier list requires current, source-linked product register and label data.
  • Without NDA/authorization identifiers and label/regulatory source text, any named supplier roster would risk being inaccurate.
  • Supplier due diligence should center on GMP status, batch release entities, and country-specific distribution documentation.

FAQs

  1. How can I identify the Estring manufacturer from the carton label?
  2. Which regulatory documents list the manufacturing and packaging sites for Estring?
  3. What information on Estring’s package insert indicates the batch release or responsible company?
  4. Do supply-chain contracts for Estring differ by country market authorization holder?
  5. How should procurement teams validate GMP compliance for Estring suppliers?

References

  1. (No source material was provided in the prompt to cite.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.